TREM-1 Pathway in Predicting Treatment Outcomes in Periodontitis

NCT06715176 | Completed

• 1 other identifier: TREM-1 pathway
• Study Type: observational
• Target: 123
• Locations: 1 country
• Sites: 1

Brief Summary

This study investigated modulations in salivary triggering receptor expressed on myeloid cells (TREM)-1, peptidoglycan recognition protein 1 (PGLYRP1) and interleukin (IL)-1β levels between healthy, gingivitis and periodontitis patients, and in response to non-surgical periodontal treatment. Systemically healthy, non-smokers with gingivitis (n=31), stage III periodontitis (grade B: n=34, grade C: n=24) and periodontally-healthy controls (n=34) were recruited. Periodontitis patients (n=45) underwent non-surgical periodontal treatment. Saliva was collected at baseline (T0, all groups), and three times (T1, T3 and T6) post-treatment (periodontitis groups only). Salivary biomarkers and total protein were measured using commercial assays.

Conditions

Periodontal Diseases

Outcome Measures

Primary Outcomes (3)

• Salivary TREM-1 level

  Salivary TREM-1 concentration (pg/ml)

  Change from baseline to one, three and six months after scaling and root planing

• Salivary PGLYRP1 level

  Salivary PGLYRP1 concentration (ng/ml)

  Change from baseline to one, three and six months after scaling and root planing

• Salivary IL-1β level

  Salivary IL-1β concentration (pg/ml)

  Change from baseline to one, three and six months after scaling and root planing

Study Arms (4)

Periodontal Health

This group showed PD ≤ 3 mm with BOP \< 10 % in the entire mouth as well as no interproximal CAL or radiographic bone loss.

Other: Clinical periodontal measurements at baseline (T0); Other: Saliva collection at baseline (T0)

Gingivitis

This group exhibited PD ≤ 3 mm with BOP ≥ 30 % in the entire mouth as well as no interproximal CAL or radiographic bone loss.

Other: Clinical periodontal measurements at baseline (T0); Other: Saliva collection at baseline (T0)

Stage III, Grade B Periodontitis

This group had interproximal CAL ≥ 5 mm along with PD ≥ 6 mm and radiographic bone loss extending to the middle or apical third of the root radiographically at 30 % of the teeth or more. CAL was not caused by trauma-related gingival recession, dental caries extending into the cervical areas of the teeth, endodontic lesions draining through the marginal periodontium, and the distal bone loss in adjacent second molars due to extractions of third molars. They had ≤ 4 teeth lost owing to periodontitis. % of radiographic bone loss/age value was between 0.25 and 1.0.

Other: Clinical periodontal measurements at baseline (T0); Other: Saliva collection at baseline (T0); Other: Scaling and root planing; Other: Clinical periodontal measurements at T1, T3, and T6.; Other: Saliva collection at T1, T3, and T6.

Stage III, Grade C Periodontitis

This group had interproximal CAL ≥ 5 mm along with PD ≥ 6 mm and radiographic bone loss extending to the middle or apical third of the root radiographically at 30 % of the teeth or more. CAL was not caused by trauma-related gingival recession, dental caries extending into the cervical areas of the teeth, endodontic lesions draining through the marginal periodontium, and the distal bone loss in adjacent second molars due to extractions of third molars. They had ≤ 4 teeth lost owing to periodontitis. % of radiographic bone loss/age were value was higher than 1.0.

Other: Clinical periodontal measurements at baseline (T0); Other: Saliva collection at baseline (T0); Other: Scaling and root planing; Other: Clinical periodontal measurements at T1, T3, and T6.; Other: Saliva collection at T1, T3, and T6.

Interventions

Clinical periodontal measurements at baseline (T0) OTHER

Full-mouth clinical periodontal measurements, including PD, CAL, GI, and PI were recorded at 6 sites per tooth, except the third molars, at baseline (T0). A manual periodontal probe was used for PD (millimeters) and CAL (millimeters) measurements; the cemento-enamel junction was used as a reference point for the measurement of CAL.

Gingivitis; Periodontal Health; Stage III, Grade B Periodontitis; Stage III, Grade C Periodontitis

Saliva collection at baseline (T0) OTHER

Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.

Gingivitis; Periodontal Health; Stage III, Grade B Periodontitis; Stage III, Grade C Periodontitis

Scaling and root planing OTHER

Periodontitis patients (grade B and C) underwent a program of non-surgical periodontal therapy consisting of conventional quadrant-based scaling and root planing using ultrasonic instruments and manual periodontal curette over four visits at 1-week intervals. All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Patients who did not respond to treatment at baseline (T0) received a further round of scaling and root planing at three (T3) months post-therapy in order to eliminate residual pockets.

Stage III, Grade B Periodontitis; Stage III, Grade C Periodontitis

Clinical periodontal measurements at T1, T3, and T6. OTHER

Full-mouth clinical periodontal measurements were performed for all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.

Stage III, Grade B Periodontitis; Stage III, Grade C Periodontitis

Saliva collection at T1, T3, and T6. OTHER

Unstimulated whole saliva were collected from all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.

Stage III, Grade B Periodontitis; Stage III, Grade C Periodontitis

Eligibility Criteria

• Age: 20 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

For this observational study, systemically healthy, non-smokers with gingivitis (n = 31), stage III, grade B periodontitis (n = 34), stage III, grade C periodontitis (n = 24), and periodontally healthy controls (n = 34) were consecutively recruited at the Department of Periodontology, School of Dentistry, Aydın Adnan Menderes University, Aydın, Turkey.

You may qualify if:

• systemically healthy
• non-smoker individuals

You may not qualify if:

• pregnancies or lactation
• to exposure to antibiotics or any other drugs that were known to affect periodontal conditions over the past 6 months prior to recruitment.
• to receive previous surgical/nonsurgical periodontal treatment during the previous 12-months.

Sponsors & Collaborators

• Aydin Adnan Menderes University: lead

Study Sites (1)

Aydın Adnan Menderes University, Faculty of Dentistry, Department of Periodontology

Aydin, 90100, Turkey (Türkiye)

Location

Related Publications (1)

• Silbereisen A, Lira-Junior R, Afacan B, Ozturk OV, Emingil G, Bostanci N. TREM-1 Pathway Biomarkers for Classification of Periodontal Diseases and Monitoring of Treatment Response in Grade B and C Periodontitis. J Clin Periodontol. 2025 Sep;52(9):1288-1297. doi: 10.1111/jcpe.14195. Epub 2025 Jun 17.

  PMID: 40528650 DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

Unstimulated whole saliva

MeSH Terms

Conditions

Periodontal Diseases

Interventions

Tooth Exfoliation; Root Planing; Triiodothyronine

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Dental Physiological Phenomena; Digestive System and Oral Physiological Phenomena; Dental Scaling; Dental Prophylaxis; Periodontics; Dentistry; Subgingival Curettage; Preventive Dentistry; Thyronines; Thyroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Thyroxine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Amino Acids, Peptides, and Proteins

Study Officials

• Nagihan Bostanci

  Karolinska Institutet

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof.

Study Record Dates

• First Submitted: November 28, 2024
• First Posted: December 4, 2024
• Study Start: December 19, 2016
• Primary Completion: January 3, 2018
• Study Completion: November 29, 2019
• Last Updated: December 4, 2024

Record last verified: 2024-12

Locations

TU (1)